A guide to how FDA expects you to measure what matters to patients
Measuring What Matters to Patients
A guide to how FDA expects you to measure what matters to patients
In a clinical trial, FDA wants to know one thing.
Did the treatment help patients in a way they actually care about?
To answer that, you need a way to measure it. That measure is called a COA.
Clinical Outcome Assessment.
It describes how a patient feels, functions, or survives.
That's it.
The difference is who does the reporting.
The patient.
Someone who watches the patient.
A clinician.
The patient doing a task.
Because what you measure is what you can claim.
A strong COA shows the benefits patients feel in daily life. That's how you set your asset apart. It also gives payers and physicians a clearer value story.
Measure it poorly, and that benefit may never make it to your label.
Something about daily life. How they feel, or what they can do.
FDA calls this the Meaningful Aspect of Health.
The specific thing that shows how the treatment affects what matters to the patient.
FDA calls this the Concept of Interest.
How the scores become an endpoint, and how you'll interpret it.
FDA calls this the Context of Use.
What matters to patients.
What you measure.
How you use it.
FDA wants each one spelled out clearly.
Start by looking for a COA that already exists. Three things can happen.
Use it.
Modify it.
Build a new one.
If you modify or build, you also collect evidence that it works.
A fit-for-purpose COA.
That means it's been validated enough to support the way you're using it.
You explain why your COA works. Then you back it up with evidence. FDA lists eight things to cover. They boil down to three questions.
Is it clear why you chose this type of COA?
Does it cover everything important about what you're measuring?
Is it given to patients properly?
Do people understand the questions the way they were meant?
Is it scored in a way that fits what you're measuring?
Are they free from things you didn't mean to measure?
Are they free from too much measurement error?
Do they reflect what matters to patients?
The COA is the tool. The questions, instructions, and scoring rules.
The score is the number it produces.
The endpoint is what you analyze. Like the average score at 12 weeks.
Early.
Early-phase trials are the best time to test your COA. Don't wait for the registration trial.
If that's not possible, FDA recommends a separate observational study first. And ask FDA for input as early as you can.
Every measurement choice should answer:
"Does this show how the treatment affects what matters to patients?"
Based on FDA's guidance snapshot, Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Not a substitute for the guidance document.
No. The right type depends on who can best report the concept of interest. Some patients can't reliably report for themselves, such as young children or people with significant cognitive impairment. An ObsRO or ClinRO may fit better there. A PerfO fits when the concept is something the patient does, like walking a set distance.
Choose the reporter based on the concept, not on habit.
Often, yes. But prior use is not the same as being fit-for-purpose. FDA looks at whether the tool works in your population and your context of use. A measure that performed well in adults with one condition may need additional evidence before it can support an endpoint in children or in a different disease.
An existing tool is a head start, not a guarantee.
A statistically significant difference is not always a change patients would notice. FDA expects sponsors to explain what size of change is meaningful to patients. This is often supported by anchor-based methods, such as patient global ratings of change, along with qualitative input from patients.
Define what "better" means before the data comes in.
Partly. The same measures that support a label claim can strengthen payer and HTA arguments. But many HTA bodies also want generic, preference-based measures, such as the EQ-5D, to feed economic models. Planning for both early lets one trial answer both sets of questions.
Regulators and payers ask different questions of the same trial.
At Alkemi, we help biotechnology and pharmaceutical companies select, modify, and develop clinical outcome assessments that fit their concept of interest and context of use. We connect COA decisions to the broader evidence plan, so the benefits patients feel can reach the label and support the value story.
If you're designing an early-phase trial or preparing for an FDA meeting and want to check that your measures will support the claims you need, let's talk.
